Citranvi Biosciences is a preclinical stage company led by a seasoned leadership team with significant experience in technologies for clinical development and commercialization of vaccines. Citranvi has obtained a worldwide exclusive from the Henry Jackson Foundation (HJF) for the Advancement of Military Medicine to develop vaccines utilizing HJF’s herpesvirus protein multimeric technology platform. Research for these technologies was conducted by Department of Defense (DoD) researchers at the Uniformed Services University of the Health Sciences and patented by HJF. Citranvi will first develop two multiantigen vaccines against infectious diseases caused by: (1) human cytomegalovirus (hCMV) and (2) Epstein-Barr virus (EBV) for which at present there are no licensed vaccines. The goal for Citranvi is to advance the two vaccine candidates (hCMV & EBV) into Phase 1 and Phase 2 clinical trials to evaluate safety and immunogenicity to support Phase 3 trials and commercialization.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Herpesvirus vaccines, Cytomegalovirus and Epstein-Barr virus
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):